MA46890A - Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme - Google Patents
Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long termeInfo
- Publication number
- MA46890A MA46890A MA046890A MA46890A MA46890A MA 46890 A MA46890 A MA 46890A MA 046890 A MA046890 A MA 046890A MA 46890 A MA46890 A MA 46890A MA 46890 A MA46890 A MA 46890A
- Authority
- MA
- Morocco
- Prior art keywords
- complications
- acute
- improvement
- reduction
- long
- Prior art date
Links
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000002641 glycemic effect Effects 0.000 title 1
- 108010050259 insulin degludec Proteins 0.000 title 1
- 229960004225 insulin degludec Drugs 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16200993 | 2016-11-28 | ||
| EP17162803 | 2017-03-24 | ||
| EP17174687 | 2017-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46890A true MA46890A (fr) | 2021-04-28 |
Family
ID=60702634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046890A MA46890A (fr) | 2016-11-28 | 2017-11-28 | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11673933B2 (https=) |
| EP (1) | EP3544682A1 (https=) |
| JP (1) | JP2019535791A (https=) |
| CN (1) | CN110099719A (https=) |
| MA (1) | MA46890A (https=) |
| WO (1) | WO2018096163A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019535791A (ja) | 2016-11-28 | 2019-12-12 | ノヴォ ノルディスク アー／エス | 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク |
| US11278596B2 (en) | 2016-11-28 | 2022-03-22 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| TWI797133B (zh) | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | 用於經口投予的固體組成物 |
| US20230158234A1 (en) * | 2021-11-22 | 2023-05-25 | Colleen Cook | Method of Insulin Administration |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| CA2531988C (en) | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| JP2015512908A (ja) * | 2012-03-28 | 2015-04-30 | サノフイ | 基礎インスリン療法 |
| CN105188736A (zh) * | 2013-03-20 | 2015-12-23 | 诺和诺德股份有限公司 | 胰岛素给药方案 |
| EP2991672A1 (en) * | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| JP2019535791A (ja) | 2016-11-28 | 2019-12-12 | ノヴォ ノルディスク アー／エス | 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク |
-
2017
- 2017-11-28 JP JP2019528540A patent/JP2019535791A/ja not_active Withdrawn
- 2017-11-28 US US16/463,594 patent/US11673933B2/en active Active
- 2017-11-28 CN CN201780073532.XA patent/CN110099719A/zh not_active Withdrawn
- 2017-11-28 WO PCT/EP2017/080603 patent/WO2018096163A1/en not_active Ceased
- 2017-11-28 EP EP17816532.0A patent/EP3544682A1/en not_active Withdrawn
- 2017-11-28 MA MA046890A patent/MA46890A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200181222A1 (en) | 2020-06-11 |
| CN110099719A (zh) | 2019-08-06 |
| WO2018096163A1 (en) | 2018-05-31 |
| JP2019535791A (ja) | 2019-12-12 |
| EP3544682A1 (en) | 2019-10-02 |
| US11673933B2 (en) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46890A (fr) | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme | |
| IL273620A (en) | Recombinant collagen and elastin molecules and their uses | |
| EP3746870A4 (en) | ECLIPSE CURSOR FOR VIRTUAL CONTENT IN MIXED REALITY DISPLAYS | |
| EP3437495A4 (en) | CARTRIDGE FOR TASTE INHALER AND TASTE INHALATOR | |
| EP3392324A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| EP3323873A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| EP3392325A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| MX380322B (es) | Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1). | |
| PT3317301T (pt) | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 | |
| EP3327101A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| IL248508B (en) | Compositions comprising aav expressing dual antibody constructs and uses thereof | |
| EP3275973A4 (en) | Liquid crystal composition and liquid crystal display element | |
| EP3495016A4 (en) | CANNULAR ARRANGEMENT WITH VALVE AND DWELLING ASSEMBLY | |
| EP3450523A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| EP2951575A4 (en) | BIOMARKERS OF TYPE 2 DIABETES AND USES THEREOF | |
| PL3247388T3 (pl) | Rekombinowany ludzki/bydlęcy wirus paragrypy 3 (b/hpiv3) eksprymujący chimeryczne białko f rsv/bpiv3 i jego zastosowania | |
| BR112018067731A2 (pt) | coagonistas de glucagon e glp-1 para o tratamento de obesidade | |
| EP3302621A4 (en) | PROCESS-BASED PROGRAMMING FOR INFUSION PUMPS | |
| EP3425025A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| GB2553706B (en) | Electro-optic and thermo-optic modulator | |
| IL268874B1 (en) | Peptides and methods for the treatment of diabetes | |
| EP2884334A4 (en) | LIQUID CRYSTAL DISPLAY ELEMENT | |
| EP3459934A4 (en) | POLYMERIZABLE COMPOUND AND COMPOSITION, LIQUID CRYSTAL COMPOSITE, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY ELEMENT AND USE THEREOF | |
| EP3541429A4 (en) | INTRATHECAL ADMINISTRATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS CODING FOR METHYL-CPG-BINDING PROTEIN 2 | |
| EP4190906C0 (en) | MODIFIED POLYPEPTIDES DERIVED FROM ADENOVIRAL FIBER PROTEIN AND VLPS CONTAINING POLYPEPTIDES |